

Contents

| | |
|--|-----------|
| List of Abbreviations | ix |
| Foreword | xi |
| Preface | xv |
| Acknowledgements | xix |
| Contributors | xxi |
| | |
| PART I Set: Understanding and assessment of peritoneal disease | 1 |
| <hr/> | |
| 1 Appendix tumours and pseudomyxoma peritonei: A 'paradigm' for peritoneal disease | 3 |
| <i>Akash Mehta and Tom Cecil</i> | |
| 2 Colorectal peritoneal metastases | 17 |
| <i>John Bunni and Brendan Moran</i> | |
| 3 Peritoneal mesothelioma | 35 |
| <i>Faraz Khan and Faheez Mohamed</i> | |
| 4 Miscellaneous peritoneal malignancies | 43 |
| <i>Andreas Brandl and Akash Mehta</i> | |
| 5 Quantitative assessment of peritoneal disease | 51 |
| <i>John Bunni and Sanjeev Dayal</i> | |
| 6 Imaging in peritoneal malignancy | 59 |
| <i>Anuradha Chandramohan and Andrew Thrower</i> | |
| | |
| PART II Dialogue: Intraperitoneal chemotherapy and cytoreductive surgery | 75 |
| <hr/> | |
| 7 Intraperitoneal chemotherapy | 77 |
| <i>Akash Mehta and Faheez Mohamed</i> | |
| 8 Perioperative and anaesthetic care | 89 |
| <i>Nina Ashraf-Kashani and John Bell</i> | |
| 9 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | 97 |
| <i>John Bunni and Tom Cecil</i> | |
| 10 Postoperative care | 113 |
| <i>Nina Ashraf-Kashani and James Coakes</i> | |
| 11 Postoperative complications | 119 |
| <i>Kim Govaerts and Brendan Moran</i> | |

| | |
|--|------------|
| PART III Closure: Ongoing care and future management options | 127 |
| 12 Histopathological aspects of peritoneal malignancy <i>Babatunde Rowaiye and Norman Carr</i> | 129 |
| 13 Follow-up protocols in peritoneal malignancy <i>Anuradha Chandramohan, Sourav Panda and Nehal Shah</i> | 147 |
| 14 Recurrence of pseudomyxoma peritonei <i>Jamish Gandhi and Alexios Tzivanakis</i> | 157 |
| 15 Future perspectives in peritoneal malignancy <i>Ioanna Panagiotopoulou, Alexios Tzivanakis and Tom Cecil</i> | 163 |
| Index | 183 |

List of Abbreviations

| | | | |
|-------|--|---------------|--|
| 5FU | 5-Fluorouracil | ICAM-1 | Intercellular adhesion molecule 1 |
| AUC | Area under the curve | IL-1 β | Interleukin-1 beta |
| BSO | Bilateral salpingo-oophorectomy | IP | Intraperitoneal |
| C_b | Concentration in the systemic circulation | IPFC | Intraperitoneal free cancer cells |
| CMS | Consensus molecular subtypes | IV | Intravenous |
| C_p | Concentration in the peritoneal cavity circulation | LAMN | Low-grade appendiceal mucinous neoplasm |
| CPM | Colorectal peritoneal metastases | LV | Leucovorin |
| CRLM | Colorectal liver metastases | MMC | Mitomycin C |
| CRS | Cytoreductive surgery | MRI | Magnetic resonance imaging |
| CT | Computed tomography | Ox | Oxaliplatin |
| DMPM | Diffuse malignant peritoneal mesothelioma | PCI | Peritoneal Cancer Index |
| DW-WB | Whole-body diffusion-weighted MRI | PIPAC | Pressurized intraperitoneal aerosol chemotherapy |
| EPIC | Early postoperative intraperitoneal chemotherapy | PMP | Pseudomyxoma peritonei |
| ESSO | European Society of Surgical Oncology | PSOGI | Peritoneal Surface Oncology Group International |
| GPM | Gastric peritoneal metastases | R_d | Pharmacokinetic advantage |
| HAMN | High-grade appendiceal mucinous neoplasm | TME | Total mesorectal excision |
| HIPEC | Hyperthermic intraperitoneal chemotherapy | TNF- α | Tumour necrosis factor-alpha |
| | | VCAM-1 | Vascular cell adhesion molecule 1 |
| | | WDPM | Well-differentiated papillary mesothelioma |